Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation

Transfusion

Volumn 54, Issue 11, 2014, Pages 2953-2960

  Billen, Annelies ^a,b   Madrigal, J Alejandro ^a,b   Szydlo, Richard M ^c   Shaw, Bronwen E ^a,b,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Anthony Nolan   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BLOOD VOLUME; BODY WEIGHT; CENTRAL VENOUS CATHETER; DEMOGRAPHY; DONOR; FEMALE; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECIPIENT; SEX; ADOLESCENT; ALLOGRAFT; BLOOD DONOR; CLINICAL TRIAL; CYTOLOGY; HEMATOPOIETIC STEM CELL; MIDDLE AGED; SEXUAL DEVELOPMENT;

CD34 ANTIGEN;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIGENS, CD34; BLOOD DONORS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SEX CHARACTERISTICS;

EID: 84912070193     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12720     Document Type: Article

References (44)

1. Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
2. Shpall EJ, Champlin R, Glaspy JA,. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
3. Mehta J, Mehta J, Frankfurt O, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009; 50: 1434-1441.
4. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114: 2606-2616.
5. Heimfeld S,. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31: 839-845.
6. Nakamura R, Auayporn N, Smith DD, et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008; 14: 449-457.
7. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
8. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.
9. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
10. Holig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-3763.
11. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 2013; 121: 197-206.
12. Pulsipher M,. Increased risk of severe adverse events after BM vs PBSC donation: results of a prospective study of 9494 NMDP donors (2004-2009). 2012 [cited 2014 Jan 1]. Available from: http://www.worldmarrow.org/fileadmin/Meeting/IDRC-Presentations/2012-IDRC-Sydney/20120504-Pulsipher.pdf
13. Stroncek DF, Clay ME, Jaszcz W, et al. Collection of two peripheral blood stem cell concentrates from healthy donors. Transfus Med 1999; 9: 37-50.
14. WMDA MWG. Minimum criteria needed for a specific donor to be available to a specific patient. 2010 [cited 2014 Jan 1]. Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/DOC/20100101-CLWG-PPR-Cell-Dose.pdf
15. WMDA MWG. Summary of the responses to the "cell dose survey." 2009 [cited 2014 Jan 1]. Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/DOC/20100101-CLWG-SURV-Cell-Dose.pdf
16. Barnett D, Janossy G, Lubenko A, et al. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol 1999; 21: 301-308.
17. Ings SJ, Balsa C, Leverett D, et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-525.
18. Shimizu N, Asai T, Hashimoto S, et al. Mobilization factors of peripheral blood stem cells in healthy donors. Ther Apher 2002; 6: 413-418.
19. Martino M, Callea I, Condemi A, et al. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). J Clin Apher 2006; 21: 169-175.
20. Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-512.
21. Fischer JC, Frick M, Wassmuth R, et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130: 740-746.
22. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092-2100.
23. Miflin G, Charley C, Stainer C, et al. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 1996; 95: 345-348.
24. Lysak D, Koza V, Jindra P,. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci 2005; 33: 275-283.
25. Sohn SK, Kim JG, Chae YS, et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apher 2003; 18: 10-15.
26. Lopez-Holgado N, Pata C, Villaron E, et al. Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors. Haematologica 2005; 90: 353-359.
27. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005; 89: 229-235.
28. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611.
29. Chen SH, Yang SH, Chu SC, et al. The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization. Int J Hematol 2011; 93: 652-659.
30. Passos-Coelho JL, Machado MA, Lucio P, et al. Large-volume leukaphereses may be more efficient than standard-volume leukaphereses for collection of peripheral blood progenitor cells. J Hematother 1997; 6: 465-474.
31. Diaz MA, Sevilla J, de la Rubia J, et al. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica 2003; 88: 919-922.
32. Bojanic I, Dubravcic K, Batinic D, et al. Large volume leukapheresis: efficacy and safety of processing patient's total blood volume six times. Transfus Apher Sci 2011; 44: 139-147.
33. Demirer T, Dagli M, Ilhan O, et al. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters. Bone Marrow Transplant 2002; 29: 893-897.
34. Schwarer AP, Messino NM, Gibson M, et al. A randomized trial of leukapheresis volumes, 7 L versus 10 L: an assessment of efficacy and patient tolerance. J Hematother Stem Cell Res 2000; 9: 269-274.
35. Kroger N, Zeller W, Hassan HT, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 microg/kg) compared to a single dose (1 × 10 microg/kg). Bone Marrow Transplant 1999; 23: 125-129.
36. Arbona C, Prosper F, Benet I, et al. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998; 22: 39-45.
37. Kroger N, Renges H, Kruger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-765.
38. de la Rubia J, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42: 4-9.
39. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998.
40. Leotta S, Poidomani M, Mauro E, et al. AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant 2011; 46: 314-316.
41. Hauge AW, Haastrup EK, Sengelov H, et al. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014; 54: 1055-1058.
42. Neumann T, Kruger WH, Busemann C, et al. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant 2011; 46: 762-763.
43. Schriber J, Fauble V, Sproat LO, et al. Plerixafor "just in time" for stem cell mobilization in a normal donor. Bone Marrow Transplant 2011; 46: 1026-1027.
44. Juarez JG, Harun N, Thien M, et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood 2012; 119: 707-716.